AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12006897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 10187944 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined steroid therapy (nasal budesonide spray 2 x 0.1 mg/day and oral fluocortolone with a total dose of 560 mg over 12 days)
Number of subjects: 20
Study 10187944 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined steroid therapy (nasal budesonide spray 2 x 0.1 mg/day and oral fluocortolone with a total dose of 715 mg over 20 days)
Number of subjects: 20
Study 10187944 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined steroid therapy
Number of subjects: 20
Study 7738344 — intervention group
Group type: EXPERIMENTAL
Intervention: Lugol's solution (approximately 170 ppm free molecular iodine)
Number of subjects: 0
Study 7738344 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level povidone-iodine preparations (0.5-20 ppm free iodine)
Number of subjects: 0
Study 7738344 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial povidone-iodine preparation
Number of subjects: 0
Study 2262896 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine withdrawal (100 mg/day)
Number of subjects: 7
Study 2262896 — intervention group
Group type: COMPARATOR
Intervention: Placebo (substituted for caffeine)
Number of subjects: 7
Study 6968819 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic electrical stimulation of the cerebellum
Number of subjects: 14
Study 6968819 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic electrical stimulation of the cerebellum (on stimulation)
Number of subjects: 14
Study 6968819 — intervention group
Group type: COMPARATOR
Intervention: Chronic electrical stimulation of the cerebellum (off stimulation)
Number of subjects: 14
Study 30888265 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorine disinfection (Aquatabs)
Number of subjects: 0
Study 30888265 — intervention group
Group type: EXPERIMENTAL
Intervention: Flocculent disinfection (Procter and Gamble Purifier of Water [P&G PoW])
Number of subjects: 0
Study 30888265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic Filters
Number of subjects: 0
Study 30888265 — intervention group
Group type: COMPARATOR
Intervention: Standard SAM treatment protocol
Number of subjects: 0
Study 29084313 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral FUS thalamotomy
Number of subjects: 27
Study 29084313 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 27
Study 24433223 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac+heparin
Number of subjects: 104
Study 24433223 — intervention group
Group type: COMPARATOR
Intervention: diclofenac
Number of subjects: 104
Study 24433223 — intervention group
Group type: COMPARATOR
Intervention: heparin
Number of subjects: 104
Study 24433223 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 104
Study 23939867 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1% lidocaine)
Number of subjects: 76
Study 23939867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 21063131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.25 mg/day
Number of subjects: 154
Study 21063131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.5 mg/day
Number of subjects: 154
Study 21063131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.75 mg/day
Number of subjects: 154
Study 21063131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.25 mg/day (week 2)
Number of subjects: 154
Study 19101255 — intervention group
Group type: EXPERIMENTAL
Intervention: Proficiency-based laparoscopic suturing simulator training
Number of subjects: 66
Study 19101255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intertraining intervals (1 to 43 days)
Number of subjects: 66
Study 19101255 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter intertraining intervals
Number of subjects: 66
Study 17322624 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide 25 mg BID
Number of subjects: 143
Study 17322624 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide 50 mg BID
Number of subjects: 143
Study 17322624 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide 100 mg BID
Number of subjects: 143
Study 17322624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 15985570 — intervention group
Group type: EXPERIMENTAL
Intervention: PSP patients (n=21)
Number of subjects: 100
Study 15985570 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects (n=31)
Number of subjects: 100
Study 15985570 — intervention group
Group type: COMPARATOR
Intervention: PD patients (n=23)
Number of subjects: 100
Study 15985570 — intervention group
Group type: COMPARATOR
Intervention: MSA-P patients (n=25)
Number of subjects: 100
Study 12574046 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised clinical decision support system
Number of subjects: 53
Study 10563031 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (33% increase in daily dosage)
Number of subjects: 18
Study 10563031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8690830 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (5, 10, and 20 mg/70 kg)
Number of subjects: 11
Study 8690830 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.125, 0.25, and 0.50 mg/70 kg)
Number of subjects: 11
Study 8690830 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (15, 30, and 60 mg/70 kg)
Number of subjects: 11
Study 8690830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1988895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 102
Study 1988895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 102
Study 1988895 — intervention group
Group type: COMPARATOR
Intervention: Upper genital tract isolates (Group B streptococcus, Enterococcus faecalis)
Number of subjects: 102
Study 1988895 — intervention group
Group type: COMPARATOR
Intervention: Upper genital tract isolates (Enterococcus faecalis)
Number of subjects: 102
Study 6122099 — intervention group
Group type: EXPERIMENTAL
Intervention: GL enzyme (hyaluronidase)
Number of subjects: 483
Study 6122099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study 30782952 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based neck-specific exercises (NSE) for 3 months
Number of subjects: 140
Study 30782952 — intervention group
Group type: COMPARATOR
Intervention: Prescribed physical activity (PPA) for 3 months
Number of subjects: 140
Study 28436479 — intervention group
Group type: EXPERIMENTAL
Intervention: NP/NC with additional TCM (n=156)
Number of subjects: 314
Study 28436479 — intervention group
Group type: COMPARATOR
Intervention: NP/NC (control, n=158)
Number of subjects: 314
Study 27629730 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin + 10 mg ezetimibe therapy for 6 months
Number of subjects: 18
Study 27629730 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin for 6 months
Number of subjects: 18
Study 27629730 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 18
Study 24886536 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse for 4 weeks
Number of subjects: 50
Study 24886536 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse for 4 weeks
Number of subjects: 50
Study 24886536 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CHX and placebo)
Number of subjects: 50
Study 21933330 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin and lifestyle intervention (low glycaemic index diet and exercise programme)
Number of subjects: 40
Study 21933330 — intervention group
Group type: COMPARATOR
Intervention: Control group (ADT alone)
Number of subjects: 40
Study 19222309 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention training condition (n = 18)
Number of subjects: 36
Study 19222309 — intervention group
Group type: COMPARATOR
Intervention: Control dot-probe task condition (n = 18)
Number of subjects: 36
Study 17997224 — intervention group
Group type: EXPERIMENTAL
Intervention: Sativex (oro‐mucosal THC: CBD)
Number of subjects: 125
Study 17997224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 17997224 — intervention group
Group type: EXPERIMENTAL
Intervention: Sativex
Number of subjects: 125
Study 16025924 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11925283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 20 microg/day
Number of subjects: 185
Study 11925283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 100 microg/day
Number of subjects: 185
Study 11925283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 9419299 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic intraoperative ultrasonography (LIOU)
Number of subjects: 518
Study 9419299 — intervention group
Group type: COMPARATOR
Intervention: Dynamic intraoperative cholangiography (IOC)
Number of subjects: 518
Study 7611266 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron dextran (100 mg twice weekly)
Number of subjects: 52
Study 7611266 — intervention group
Group type: COMPARATOR
Intervention: Oral iron therapy
Number of subjects: 52
Study 2171050 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler US
Number of subjects: 14
Study 2171050 — intervention group
Group type: COMPARATOR
Intervention: Digital angiography
Number of subjects: 14
Study 380915 — intervention group
Group type: EXPERIMENTAL
Intervention: Amineptine (200 mg per day)
Number of subjects: 51
Study 380915 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (75 mg per day)
Number of subjects: 51
Study 30683146 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% simvastatin-acid sodium salt ointment
Number of subjects: 24
Study 30683146 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% atorvastatin calcium salt ointment
Number of subjects: 24
Study 30683146 — intervention group
Group type: COMPARATOR
Intervention: Vehicle ointment (control)
Number of subjects: 24
Study 28454798 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 to 320 mg daily
Number of subjects: 0
Study 28454798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26054142 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of Zhuang medicine at Qineihuan point and conventional acupuncture
Number of subjects: 60
Study 26054142 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 60
Study 24060346 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA (an unspecific nitric oxide synthase inhibitor)
Number of subjects: 12
Study 24060346 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (an α‐adrenoceptor agonist)
Number of subjects: 12
Study 24060346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 20878646 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant treatments
Number of subjects: 537
Study 20878646 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 537
Study 20878646 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue and depression
Number of subjects: 537
Study 20878646 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index and comorbidity
Number of subjects: 537
Study 19684412 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigorous volume management during thrice-weekly hemodialysis
Number of subjects: 22
Study 17412579 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation (1500 mg/day)
Number of subjects: 8
Study 17412579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 17412579 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 8
Study 15805763 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 0
Study 15805763 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 0
Study 11422135 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses from three of the eight questions for adults
Number of subjects: 922
Study 11422135 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses from two questions for children
Number of subjects: 922
Study 11422135 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall model for both age groups
Number of subjects: 922
Study 9631604 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic uterine arterial separation with coagulation (Group 1)
Number of subjects: 70
Study 9631604 — intervention group
Group type: COMPARATOR
Intervention: Uterine artery coagulated by bipolar electrocoagulator through vaginal route (Group 2)
Number of subjects: 70
Study 7946367 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (loading dose 1.5 micrograms/kg, infusion rate 1 micrograms/kg/hr)
Number of subjects: 54
Study 7946367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) fentanyl (loading dose 1.5 micrograms/kg, infusion rate 1 micrograms/kg/hr)
Number of subjects: 54
Study 7946367 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (75 micrograms/hr)
Number of subjects: 54
Study 7946367 — intervention group
Group type: COMPARATOR
Intervention: Epidural fentanyl
Number of subjects: 54
Study 7946367 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) fentanyl
Number of subjects: 54
Study 7946367 — intervention group
Group type: COMPARATOR
Intervention: Transdermal fentanyl
Number of subjects: 54
Study 3499244 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (PROP), 2.5 mg . kg‐1
Number of subjects: 180
Study 3499244 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone (THIO), 4 mg . kg‐1
Number of subjects: 180
Study 3499244 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone (METH), 1.5 mg . kg‐1
Number of subjects: 180
Study 3499244 — intervention group
Group type: COMPARATOR
Intervention: Control values (baseline measurements)
Number of subjects: 180
Study 31390087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette cue
Number of subjects: 102
Study 31390087 — intervention group
Group type: COMPARATOR
Intervention: Water cue
Number of subjects: 102
Study 28905874 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mg nicotine transdermal patch (TNP)
Number of subjects: 80
Study 28905874 — intervention group
Group type: COMPARATOR
Intervention: Placebo transdermal patch (PBO)
Number of subjects: 80
Study 28222525 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Intervention (CI)
Number of subjects: 0
Study 28222525 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 25803648 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia to a temperature of 32-33°C for 72 hours
Number of subjects: 55
Study 25803648 — intervention group
Group type: COMPARATOR
Intervention: Strict normothermia to a temperature of 36-37°C for 72 hours
Number of subjects: 55
Study 23505907 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning (PC)
Number of subjects: 45
Study 23505907 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study 21383834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile two-tap apparent-motion streams with an SOA of 400 ms, paired with auditory beeps at various SOAs (from -75 ms to 75 ms)
Number of subjects: 0
Study 21383834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile two-tap apparent-motion streams with a long SOA (325 ms) and a short SOA (75 ms), with both beeps occurring close to the taps on one side
Number of subjects: 0
Study 21383834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile two-tap apparent-motion streams with only odd-numbered taps paired with auditory beeps
Number of subjects: 0
Study 18815716 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-enriched white light (17 000 K)
Number of subjects: 94
Study 18815716 — intervention group
Group type: COMPARATOR
Intervention: White light (4000 K)
Number of subjects: 94
Study 16818281 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+‐selected peripheral blood cells (group C)
Number of subjects: 54
Study 16818281 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmanipulated marrow or blood cells (group B)
Number of subjects: 54
Study 16818281 — intervention group
Group type: COMPARATOR
Intervention: No further donor cell infusion (group A)
Number of subjects: 54
Study 12621795 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant follicle-stimulating hormone (rFSH) 100 IU
Number of subjects: 224
Study 12621795 — intervention group
Group type: COMPARATOR
Intervention: Urinary follicle-stimulating hormone (uFSH) 150 IU
Number of subjects: 224
Study 12757434 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised Controlled Trials (RCTs) in health sciences librarianship
Number of subjects: 0
Study 9457926 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH (follitropin beta, Puregon)
Number of subjects: 172
Study 9457926 — intervention group
Group type: COMPARATOR
Intervention: Urinary FSH (urofollitropin, Metrodin)
Number of subjects: 172
Study 8168027 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative evaluation and postoperative care
Number of subjects: 0
Study 8168027 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for pre-existing disease
Number of subjects: 0
Study 2679204 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized female unit (EWA)
Number of subjects: 200
Study 2679204 — intervention group
Group type: COMPARATOR
Intervention: Traditional mixed-sex alcoholism treatment centers
Number of subjects: 200
Study 1053489 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 150
Study 1053489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 29378998 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% hyaluronic acid (Gengigel) applied in postextraction sockets of the right third molars
Number of subjects: 25
Study 29378998 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment applied to extraction sockets of the left third molars)
Number of subjects: 25
Study 25497252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesion abciximab and aspiration thrombectomy
Number of subjects: 452
Study 25497252 — intervention group
Group type: COMPARATOR
Intervention: Control group (men)
Number of subjects: 452
Study 23661523 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acids and arginine enhanced formula (3 cans per day)
Number of subjects: 37
Study 23661523 — intervention group
Group type: COMPARATOR
Intervention: Omega 3 fatty acids and arginine enhanced formula (2 cans per day)
Number of subjects: 37
Study 21205136 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon (PEG‐IFN) plus low doses of ribavirin (800 mg/day) for 24 weeks
Number of subjects: 0
Study 21205136 — intervention group
Group type: EXPERIMENTAL
Intervention: shorter treatment (12‐16 weeks)
Number of subjects: 0
Study 21205136 — intervention group
Group type: EXPERIMENTAL
Intervention: shorter treatment (12‐16 weeks) in subgroup with RVR
Number of subjects: 0
Study 21205136 — intervention group
Group type: EXPERIMENTAL
Intervention: prolonging therapy
Number of subjects: 0
Study 19930696 — intervention group
Group type: EXPERIMENTAL
Intervention: HRQOL assessed using the 36-item Short-Form health survey (SF36) in CKD patients
Number of subjects: 944
Study 19930696 — intervention group
Group type: COMPARATOR
Intervention: Cumulative survival rate based on SF36 scores
Number of subjects: 944
Study 19930696 — intervention group
Group type: EXPERIMENTAL
Intervention: SF36 score (physical and mental components)
Number of subjects: 944
Study 19930696 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical components of SF36
Number of subjects: 944
Study 19930696 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental components of SF36
Number of subjects: 944
Study 17586189 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-HepB-IPV plus PCV-7 and Hib
Number of subjects: 199
Study 17586189 — intervention group
Group type: COMPARATOR
Intervention: Separate vaccines
Number of subjects: 199
Study 17586189 — intervention group
Group type: COMPARATOR
Intervention: DTaP-HepB-IPV plus Hib with PCV-7 administered 2 weeks later
Number of subjects: 199
Study 15473622 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (BM) - hyperbaric bupivacaine 0.5% 2 mL + 1 mL of 2mg preservative‐free midazolam
Number of subjects: 44
Study 15473622 — intervention group
Group type: COMPARATOR
Intervention: Group I (B) - hyperbaric bupivacaine 0.5% 2 mL + saline 0.9% 1 mL
Number of subjects: 44
Study 11303198 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg micronized 17 beta‐estradiol daily sequentially combined with 5 or 10 mg dydrogesterone for 14 days of each 28‐day cycle during 12 months and thereafter 2 mg 17 beta‐estradiol combined with 10 mg dydrogesterone for a period of 3 months
Number of subjects: 30
Study 11303198 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 9627593 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk formula (MF; 67 cal/100 ml)
Number of subjects: 96
Study 9627593 — intervention group
Group type: COMPARATOR
Intervention: Yogurt formula (YF; prepared from the same milk formula)
Number of subjects: 96
Study 9627593 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk formula (MF)
Number of subjects: 96
Study 9627593 — intervention group
Group type: COMPARATOR
Intervention: Yogurt formula (YF)
Number of subjects: 96
Study 8154907 — intervention group
Group type: EXPERIMENTAL
Intervention: Mature donor breast milk
Number of subjects: 502
Study 8154907 — intervention group
Group type: COMPARATOR
Intervention: Preterm formula
Number of subjects: 502
Study 8154907 — intervention group
Group type: COMPARATOR
Intervention: Standard term formula
Number of subjects: 502
Study 8154907 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor breast milk
Number of subjects: 502
Study 3282034 — intervention group
Group type: EXPERIMENTAL
Intervention: BW942C
Number of subjects: 30
Study 3282034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30627989 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal-jejunal bypass liner (DJBL)
Number of subjects: 29
Study 28569520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT) focused on early change
Number of subjects: 44